https://www.psychiatrist.com/esketamine-ciii-nasal-spray-treatment-resistant-depression/
The Journal of Clinical Psychiatry
Information from Industry June 30, 2020
SPRAVATO® (esketamine) CIII Nasal Spray: The First and Only N-Methyl D-Aspartate (NMDA) Receptor Antagonist Approved in Conjunction With an Oral Antidepressant for the Treatment of Adults With Treatment-Resistant Depression
Vol 87 • 2026 • Number 1
Read the Current Issue
ASCP Corner
Rethinking Amisulpride: Could N-Methylation Result in a New and Even Better Antipsychotic?
Original Research
How Many Criteria Should be Required to Define the DSM-5 Mixed Features Specifier in Depressed Patients?
Meta-Analysis
Effectiveness of Peer-Administered Interventions for Perinatal Depression or Anxiety
Original Research
Innovation in Psychiatric Drug Development: A Quantitative Analysis of FDA-Approved Psychiatric Drugs, 2012–2024
Brief Report
Exercise Reduces Dysphoria in Clinical High-Risk for Psychosis: A Randomized Controlled Trial
Clinical and Practical Psychopharmacology
Pregabalin in Pregnancy: Major Congenital Malformations, Other Birth Outcomes, and Neurodevelopmental Outcomes
Related Articles
Information from Industry
Auvelity: A Rapid-Acting Antidepressant With Multimodal Activity
September 27, 2024
AUVELITY is an FDA-approved treatment for adults with MDD. Auvelity, is a rapid-acting antidepressant with a multimodal mechanism, targeting both glutamatergic and monoaminergic pathways. Learn more about how AUVELITY...
